Journal: Scientific reports

Article Title: UCHL1, besides leptin and fibronectin, also could be a sensitive marker of the relapsing-remitting type of multiple sclerosis.

doi: 10.1038/s41598-023-30237-3

Figure Lengend Snippet: Figure 4. The correlation coefficient between fibronectin and UCHL1 concentration in relapse-remitting multiple sclerosis patients.

Article Snippet: Recombinant human UCHL1 protein and rabbit monoclonal antibody (R&D Systems, USA), recombinant human leptin protein 3 Vol.

Techniques: Concentration Assay

Journal: Scientific reports

Article Title: UCHL1, besides leptin and fibronectin, also could be a sensitive marker of the relapsing-remitting type of multiple sclerosis.

doi: 10.1038/s41598-023-30237-3

Figure Lengend Snippet: Figure 3. Plasma UCHL1 concentration in relapse-remitting multiple sclerosis patients (RRMS) as compared to the healthy control individuals. Statistical significance ***p ≤ 0.001.

Article Snippet: Recombinant human UCHL1 protein and rabbit monoclonal antibody (R&D Systems, USA), recombinant human leptin protein 3 Vol.

Techniques: Clinical Proteomics, Concentration Assay, Control

Journal: Scientific reports

Article Title: UCHL1, besides leptin and fibronectin, also could be a sensitive marker of the relapsing-remitting type of multiple sclerosis.

doi: 10.1038/s41598-023-30237-3

Figure Lengend Snippet: Figure 5. Areas under the ROC curves (AUCs) for plasma leptin, fibronectin, and UCHL1 evaluation in differentiating relapse-remitting multiple sclerosis patients from healthy individuals. For plasma leptin the AUC = 0.698, cut-off = 14.49 ng/ml; for plasma fibronectin the AUC = 0.994, cut-off = 0.94 ng/ml; for plasma UCHL1 the AUC = 0.999, cut-off = 7.63 ng/ml.

Article Snippet: Recombinant human UCHL1 protein and rabbit monoclonal antibody (R&D Systems, USA), recombinant human leptin protein 3 Vol.

Techniques: Clinical Proteomics

Journal: Cell reports. Medicine

Article Title: UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.

doi: 10.1016/j.xcrm.2023.101381

Figure Lengend Snippet: Figure 2. UCHL1 regulates cancer cell growth in vitro and in vivo (A) UCHL1 and SYP levels in 22Rv1-RFP, 22Rv1-UCHL1-OV (WT UCHL1), and 22Rv1-UCHL1(C90S) cells were determined by western blot (WB) (left). SOX2, CD56, SYP, and UCHL1 levels in UCHL1 knockout pool cells were assessed by WB (right). (B and C) Colony formation assays of 22Rv1 with or without WT UCHL1 or UCHL1(C90S) overexpression (B) and colony formation assays of TD-NEPC parental (no transfection) cells, CTL (transfection with control non-targeting sgRNA), and UCHL1 knockout (transfection with multi-sgRNA targeting UCHL1) single-cell selection clones (C). Scale bar, 1 cm. The percentage of colony area per well was quantified using ImageJ. All experiments were performed in triplicate. Error bars, SD. (D) Subcutaneous tumor growth (left) and tumor weight (right) of 22Rv1-RFP (n = 10) and 22Rv1-UCHL1-OV (n = 10). Error bars represent standard error of the mean (SEM). (E) IHC staining of UCHL1, androgen receptor (AR) and SYP, CgA, and CD56 in 22Rv1 xenografts. Scale bar, 10 mm. (F) Subcutaneous tumor growth of TD-NEPC parental (no transduction), CTL 1 and 2, and UCHL1 knockout 1, 2, and 3 single-cell selection clone xenografts. Error bars represent SEM. (G) Harvested tumors (left) and tumor weights (right) at the endpoint (scale bar, 1 cm). (H) IHC staining for UCHL1, SYP, CgA, and CD56 in TD-NEPC parental, CTL, and UCHL1 knockout (KO) xenografts. Scale bars, 10 mm. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001, determined by Student’s t test.

Article Snippet: Briefly, mouse Anti-human UCHL1 capture antibody (DY6007, 1:120, R&D Systems) diluted in 0.2 M sodium bicarbonate (pH 9.4) was coated in 96-well, half-well plates (#3690, Corning) overnight at 4 C. After washing with 0.05% Tween 20 in PBS (PBS-T) three times, the plates were blocked with 5% BSA in PBS overnight at 4 C. Then, plasma samples (50 mL) were incubated at room temperature for 2 h followed by three washes with PBS-T.

Techniques: In Vitro, In Vivo, Western Blot, Knock-Out, Over Expression, Transfection, Control, Selection, Clone Assay, Immunohistochemistry, Transduction

Journal: Cell reports. Medicine

Article Title: UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.

doi: 10.1016/j.xcrm.2023.101381

Figure Lengend Snippet: Figure 7. Inhibition of UCHL1 decreases NEPC and SCLC metastasis in vivo (A) Schematic of the intracardiac injection metastasis model for treatment with LDN. The image was generated using BioRender (https://biorender.com). (B) BLI imaging of the TD-NEPC intracardiac injection metastasis model treated with Veh or LDN on day 14 post-treatment (n = 7). The bioluminescence signal was quantified by fold change compared with day 0 (right). (C) Percentage and number of metastasis-positive animals/total animal number by organ site. (D) Representative RFP fluorescence imagines of liver (scale bar, 2 mm). The number of liver metastases was quantified by counting the RFP foci (left). (E) Representative RFP fluorescence images of bone (scale bar, 2 mm). (F) BLI of the Veh- or LDN-treated intracardiac injection model generated with NCI-H82 cells. Bioluminescence intensity was quantified by fold change compared with day 0. (G) GFP fluorescence images of liver (left). Scale bar, 2 mm. The number and size of the liver metastases were quantified by GFP signals (right). (H) GFP fluorescence images of LNs with percentage of the mice with LN metastases. Scale bar, 2 mm. *p < 0.05, **p < 0.01, assessed by Student’s t test.

Article Snippet: Briefly, mouse Anti-human UCHL1 capture antibody (DY6007, 1:120, R&D Systems) diluted in 0.2 M sodium bicarbonate (pH 9.4) was coated in 96-well, half-well plates (#3690, Corning) overnight at 4 C. After washing with 0.05% Tween 20 in PBS (PBS-T) three times, the plates were blocked with 5% BSA in PBS overnight at 4 C. Then, plasma samples (50 mL) were incubated at room temperature for 2 h followed by three washes with PBS-T.

Techniques: Inhibition, In Vivo, Injection, Generated, Imaging